CAPITOL COUNSEL LLC for GENENTECH
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICK BOUKNIGHT New | Deputy Chief of Staff, Rep. Kevin McCarthy; Deputy Chief of Staff/ Communications Dir., Rep. Kevin McCarthy; Press Sec., Rep. Kevin McCarthy; Press Sec., Rep. Bill Thomas; Deputy Press Sec., Ways and Means Cmte.; Press Asst., Ways and Means Cmte. |
| JEFFREY CARROLL | — |
| ROBERT DIAMOND | — |
| JOSEPH EANNELLO | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Health Issues HCR
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program." Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research and novel product development.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICK BOUKNIGHT New | — |
| JEFFREY CARROLL | — |
| ROBERT DIAMOND | — |
| JOSEPH EANNELLO | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.